Silo Pharma receives European patent allowance for PTSD prevention therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
April 6, 2026 4:15 PM EDTEPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio
SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (Silo or the Company), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress (European Patent Application No.... More
